Annual Report for the fiscal year 2020
February 24, 2021
Curasight A/S (“Curasight” or “the Company”) hereby publishes the Annual Report for the fiscal year 2020. The Annual Report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
Curasight’s CEO Ulrich Krasilnikoff comments:
“It’s with excitement and pride that I share Curasight’s first annual report as a listed company. The fiscal year 2020 has been a successful year for Curasight where our single most important event was the listing on the Spotlight Stock Market and connected issue of units during the fourth quarter. I want to thank everyone who subscribed in the issue of units, for your interest in Curasight and our technology. During the financial year, Curasight has made significant progress in advancing the development of its uPAR Theranostics platform, which combines radiation therapy for cancer uTREAT® (therapy) with uTRACE® (diagnostics). Combining these two methods makes it possible to detect and treat cancer and metastases in a much more gentle and efficient way than today’s method of external radiation therapy. During the financial year, the investigator-initiated clinical phase IIb trial in prostate cancer was completed. The results and knowledge obtained from the investigator-initiated diagnostic trials will form the basis for selecting relevant cancer indications and increase our possibilities for a successful progress with uTREAT®. The initiation by Curasight of a pre-clinical therapy study in Glioblastoma (brain cancer) during the fourth quarter marks the beginning of developing Curasight’s therapy method into a clinically useful method.”
Fourth quarter 2020
- Net sales amounted to 0 (0) DKK
- Operating profit/loss amounted to -4,425,970 (-301,108) DKK
- Profit/loss before taxes amounted to -4,767,110 (-675,702) DKK
- Profit/loss for the period amounted to -4,767,178 (-527,048) DKK
- Total assets amounted to 63,105,845 (22,542,380) DKK
- Equity ratio amounted to 93.7 (80.0)
- Earnings per share amounted to -0.27 (-0.04*)
January – December 2020
- Net sales amounted to 0 (0) DKK
- Operating profit/loss amounted to -4,791,150 (-738,582) DKK
- Profit/loss before taxes amounted to -5,773,575 (-1,711,630) DKK
- Profit/loss for the year amounted to -5,552,201 (-1,335,072) DKK
- Total assets amounted to 63,105,845 (22,542,380) DKK
- Equity ratio amounted to 93.7 (80.0)
- Earnings per share amounted to -0.32 (-0.10*)
* Nom. Value per share changed in 2019 from DKK 1.00 to DKK 0.05
Highlights during the period
On September 2, Curasight announced that the Company had received approval for listing at Spotlight Stock Market. The Company also published the prospectus for the issue of units.
On September 3, the subscription period for Curasight’s issue of units began.
On September 9, CEO Ulrich Krasilnikoff and CSO Andreas Kjaer presented Curasight, its operations and future plans, via a webcast with BioStock.
On September 17, the subscription period for Curasight’s issue of units ended.
On September 22, the Company announced that the initial part of the IPO of units were subscribed to approx. DKK 273 million (before issue costs), corresponding to a subscription ratio of approx. 835 percent. Curasight was therefore provided with approx. DKK 32.7 million (before issue costs). Hence, Curasight received approximately 1,700 new shareholders.On September 22, and in addition to the IPO of units, the Company has executed a directed issue of units at the same terms as the IPO, which will provide Curasight with an additional approx. DKK 14 million (before issue costs).
On October 7, Curasight announced that the Company had entered into an expansion of the agreement with TRT Innovations ApS (“TRT Innovations”), which ensures the right for the Company to broaden its activities within targeted radionuclide therapy in cancer.
On October 8 was the first day of trading with Curasight’s shares and warrants of series TO 1. The shares are traded under the ticker “CURAS” with ISIN DK0061295797 and Curasight’s warrants of series TO 1 are traded under the ticker ”CURAS TO 1” with ISIN DK0061408747.
On October 22, Curasight announced that the Company’s Canadian patent application CA 2,903,261 was ready for allowance and the patent will be issued. This patent application relates to Curasight’s imaging technology relating to uTRACE® (imaging agent 68Ga-NOTA-AE105) and uses thereof until 2034.
On November 13, Curasight announced that the Company had initiated the pre-clinical study of uPAR targeted radionuclide therapy (uTREAT®) in brain cancer and signed an agreement with the Danish CRO Minerva Imaging A/S (“Minerva Imaging”), to conduct the pre-clinical study.
On December 16, Curasight announced that the Japan Patent Office has issued a notice of allowance confirming that the Japanese Patent Application no. 2019-005811 regarding 177-Lu Labeled peptide conjugate for site specific uPAR-targeting will be granted. The patent application relates to Curasight’s therapeutic technology uTREAT® and uses thereof.
On December 21, Announcement that the Phase II investigator-initiated study in prostate cancer is to be published in an upcoming issue of the Journal of Nuclear Medicine.
Highlights after the period
On February 8, Curasight announced that the United States Patent and Trademark Office had issued a notice of allowance confirming that the United States Patent Application no. 14/399,820 regarding 177-Lu Labeled peptide conjugate for site specific uPAR-targeting will be granted.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com